



Review

Fetal origin of endocrine dysfunction in the adult: The phthalate model

D.B. Martinez-Arguelles^a, E. Campioli^a, M. Culty^{a,b}, B.R. Zirkin^c, V. Papadopoulos^{a,b,d,*}^a The Research Institute of the McGill University Health Centre and Department of Medicine, McGill University, Montreal, Quebec, Canada^b Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada^c Department of Biochemistry and Molecular Biology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA^d Department of Biochemistry, McGill University, Montreal, Quebec, Canada

ARTICLE INFO

Article history:

Received 22 October 2012

Received in revised form

27 December 2012

Accepted 7 January 2013

Keywords:

Sex-differences

Phthalate

Steroid hormones

Environment

Endocrine disruptor

ABSTRACT

Di-(2-ethylhexyl) phthalate (DEHP) is a plasticizer with endocrine disrupting properties that is found ubiquitously in the environment as well as in human amniotic fluid, umbilical cord blood, human milk, semen, and saliva. It is used in the industry to add flexibility to polyvinyl chloride-derived plastics and its wide spread use and presence has resulted in constant human exposure through fetal development and postnatal life. Epidemiological studies have suggested an association between phthalate exposures and human reproductive effects in infant and adult populations. The effects of fetal exposure to phthalates on the male reproductive system were unequivocally shown on animal models, principally rodents, in which short term deleterious reproductive effects are well established. By contrast, information on the long term effects of DEHP *in utero* exposure on gonadal function are scarce, while its potential effects on other organs are just starting to emerge. The present review focuses on these novel findings, which suggest that DEHP exerts more complex and broader disruptive effects on the endocrine system and metabolism than previously thought.

This article is part of a Special Issue entitled "CSR 2013".

© 2013 Elsevier Ltd. All rights reserved.

Contents

1. Introduction	6
2. Steroidogenesis	6
3. Development	6
3.1. Testes	6
3.2. Ovary	7
3.3. Adrenal gland	7
4. DEHP	8
4.1. Pharmacokinetics	8
4.2. DEHP metabolites activate the PPAR receptors	8
4.3. <i>In utero</i> DEHP exposure leads to long-term effects in the adult male offspring	8
4.3.1. <i>In utero</i> DEHP exposure decreases the expression of the mineralocorticoid receptor in adult Leydig cells	8
4.3.2. <i>In utero</i> DEHP exposure targets the adult adrenal gland	9
4.3.3. <i>In utero</i> DEHP exposure affects the transport of cholesterol into the mitochondria	10
4.3.4. <i>In utero</i> DEHP exposure decreased the systemic blood pressure in the elderly rat	10
4.3.5. Effects of <i>in utero</i> DEHP exposure on liver carrier proteins	10

Abbreviations: 22R-OHC, 22R-hydroxycholesterol; ACTH, adrenocorticotropic hormone; ALC, adult Leydig cells; ATIIR, angiotensin receptor; DEHP, di-(2-ethylhexyl) phthalate; DHEA, dehydroepiandrosterone; DHEAS, sulfated dehydroepiandrosterone; EHXA, 2-ethylhexanoic acid; FSH, follicle-stimulating hormone; GD, gestational day; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; MEHP, mono(2-ethylhexyl) phthalate; MIS, Müllerian inhibitory substance; MR, mineralocorticoid receptor; MSRF, methylation-sensitive restriction finger printing; PND, postnatal day; PPAR, peroxisome proliferator activated receptor; PVC, polyvinyl chloride; ROS, reactive oxygen species; SRY, sex-determining region of the Y chromosome; STAR, steroidogenic acute regulatory protein; T3, triiodothyronine; T4, thyroxine; TDS, testicular dysgenesis syndrome; TSH, thyroid stimulating hormone; TSPO, translocator protein (18-kDa); ZG, zona glomerulosa; ZF, zona fasciculata; ZR, zona reticularis.

* Corresponding author at: The Research Institute of the McGill University Health Centre, Montreal General Hospital, 1650 Cedar Avenue, Room C10-148, Montréal, Québec, H3G 1A4 Canada. Tel.: +1 514 934 1934x44580; fax: +1 514 934 8439.

E-mail addresses: vassilios.papadopoulos@mcgill.ca, papadopv@aol.com (V. Papadopoulos).

4.3.6.	Effects of <i>in utero</i> DEHP exposure on thyroid function	11
4.3.7.	Epigenetic evidence for long term effects of DEHP	11
4.3.8.	<i>In utero</i> exposure to DEHP suggested the existence of an adrenal-testis axis	12
4.4.	DEHP in the female	12
4.4.1.	Female effects after postnatal exposure to DEHP	12
4.4.2.	<i>In utero</i> exposure to DEHP exerts long term effect in the female offspring	12
4.5.	DEHP and the pituitary–gonadal axis	12
4.6.	DEHP and ROS	13
5.	Conclusions	13
	Competing interest	13
	Acknowledgments	13
	References	13

1. Introduction

Phthalate esters are used in industry as plasticizers to add softness and flexibility to polyvinyl chloride (PVC) plastics. Phthalate-free PVC is white and rigid, but with the addition of phthalates it can be molded and used for a wide variety of products, including personal care products, toys, food wrappings, medical devices, lubricants, waxes, insecticides, and building and household products among many others [1,2]. Interestingly, medical devices have been identified as a potential risk to young children due to their high content of phthalates, and account for some of the highest exposures [3,4]. Studies measuring phthalate exposure in neonatal medical intensive care units found levels as high as 50 times greater than those in children between the ages of 6 and 10 years old [5–7]. Di-(2-ethylhexyl) phthalate (DEHP) is the most commonly used phthalate in industry, with three million metric tons produced each year [8]. In some instances, DEHP can account for 40% of the total weight of the product [9]. Because DEHP is not covalently bound to the PVC polymer, it leaches into the environment and comes into contact with humans mainly through dermal exposure [10], oral ingestion [9,11], and inhalation [12,13]. In humans, maternal exposure to phthalates [14–17] provides the first source of fetal exposure, and has been identified in amniotic fluid [18], umbilical cord blood [16], and other bodily fluids [19]. This exposure to phthalates continues after birth through breast feeding [20–22], baby and infant food sources [11,23,24], and contact to the environment [2]. These abundant man-made sources of phthalates result in human exposure estimated at 1.7–52.1 $\mu\text{g}/\text{kg}/\text{day}$ [4,25–27], and under specific circumstances, infants can be exposed to up to 3 times as much [1]. This is a public health concern since exposure to DEHP in rodents was found to be an endocrine disruptor, and in humans there are correlations between phthalate exposure and decreased anogenital distance [17], reduced testosterone levels [28], and poor semen quality [29–31]. These clinical findings, together with cryptorchidism, hypospadias, and testicular cancer [32], were grouped under the term testicular dysgenesis syndrome (TDS), which is thought to originate from an insult to Sertoli or Leydig cell function during development [33,34]. This has led to a focus on the possible involvement of phthalates in TDS [35], in agreement with the reported increase in cryptorchidism, hypospadias [36–39], decreased semen quality [40–42], and increased testicular cancer [35]. In the female, DEHP also targets the reproductive system, but data on the mechanisms have lagged compared to the male. New data from studies of female offspring exposed *in utero* to DEHP is suggesting sex-specific effects of phthalates [43], and that DEHP has a multiorgan effect that depends on the time of exposure.

We will review herein the data on the long-term effects of *in utero* exposure to DEHP in the male and female offspring.

2. Steroidogenesis

Systemic steroid hormones are primarily formed by the gonads, adrenal glands, and during *in utero* development by the placenta. The brain [44–46] and heart [47–49] have also been identified as steroid-producing tissues forming limited amounts of steroid hormones mainly for local needs.

Cholesterol is the building block of steroid hormone biosynthesis and the import of cholesterol into the mitochondria is the rate-limiting step of steroidogenesis (Fig. 1) [50,51]. This process is facilitated by the steroidogenic acute regulatory protein (STAR), a hormone-induced short lived protein which acts at the mitochondria to induce cholesterol transport. Steroidogenic cholesterol at the outer mitochondria membrane binds to the translocator protein (18-kDa) TSPO part of a complex of proteins which mediate cholesterol movement to the inner mitochondrial membrane where CYP11A1 cleaves the side chain of cholesterol to form pregnenolone. Production of progesterone from pregnenolone is catalyzed by 3 β HSD. Tissue specificity of steroids formed is provided by the tissue-specific expression of enzymes downstream of pregnenolone and progesterone [52]. Expression of CYP17A1 drives the production of testosterone by the Leydig cells of the testes, and in the ovary, granulosa and theca cells form estradiol from androgen. The adrenal gland is composed of three distinct layers, the outermost zona glomerulosa (ZG) which synthesizes aldosterone, the zona fasciculata (ZF) which forms cortisol, and the zona reticularis (ZR) which produces dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). It is important to note, that rodents do not express CYP17A1 in the adrenal gland and as a consequence corticosterone is the predominant glucocorticoid [53–55].

3. Development

3.1. Testes

During early sexual development in the mouse, male and female gonads are indistinguishable and dependent on the expression of the sex-determining region of the Y chromosome (SRY) to commit to male phenotype. The initial commitment of few embryonic stem cells to become primordial germ cells occurs similarly in both sexes around GD7 [56], followed by their migration into the genital ridge between GD9 and 10.5, where they become residents in the undifferentiated gonad [57]. SRY expression results in upregulation of SOX9, a key promoter of Sertoli cell differentiation, which drives the regression of the female Mullerian ducts by producing Mullerian inhibitory substance (MIS) [58]. Fetal Sertoli cells regulate the development of the primordial germ cells into the testis from day 11.5 to 13.5 post coitus [59], and regulate the formation of the seminiferous cords by controlling the spatial organization of

Download English Version:

<https://daneshyari.com/en/article/8339000>

Download Persian Version:

<https://daneshyari.com/article/8339000>

[Daneshyari.com](https://daneshyari.com)